The dopamine hypothesis of schizophrenia is based on evidence that the major antipsychotic drugs act by blocking dopamine D2 receptors and that dopamine-releasing drugs worsen symptoms. In this issue of Neuron, Kellendonk et al. report an elegant conditional transgenic mouse overexpressing dopamine D2 receptors selectively in the striatum. Strikingly, these animals display selective cognitive impairment typically associated with frontal cortical defects and abnormal dopamine markers in the prefrontal cortex, suggesting that striatal dopamine receptors can influence cortical dopamine function
Negative symptoms (NS) represent a heterogeneous dimension of schizophrenia (SCZ), associated with a...
Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. ...
The dopamine D2 and D3 receptors are implicated in schizophrenia and its pharmacological treatments....
The dopamine hypothesis of schizophrenia is based on evidence that the major antipsychotic drugs act...
Aberrant dopaminergic activity is widely believed to underlie at least some of the symptoms seen in ...
Excessive dopamine neurotransmission underlies psychotic episodes as observed in patients with some ...
Background: Schizophrenia is a disease diagnosed by visible signs and symptoms from late adolescence...
Among the many neuromodulators used by the mammalian brain to regulate circuit function and plastici...
Dysfunction in both the dopaminergic and glutamatergic systems has been implicated in the pathophysi...
The cloning of the dopamine (DA) D2 receptor now permits the characterization and regulation of D2 m...
Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. ...
Presynaptic increase in striatal dopamine is the primary dopaminergic abnormality in schizophrenia, ...
Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia. The revised d...
Published online 7 August 2007.There is growing evidence implicating dysfunctional glutamatergic neu...
Based on the observation that antipsychotic medications dis-play antagonist properties at dopamine D...
Negative symptoms (NS) represent a heterogeneous dimension of schizophrenia (SCZ), associated with a...
Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. ...
The dopamine D2 and D3 receptors are implicated in schizophrenia and its pharmacological treatments....
The dopamine hypothesis of schizophrenia is based on evidence that the major antipsychotic drugs act...
Aberrant dopaminergic activity is widely believed to underlie at least some of the symptoms seen in ...
Excessive dopamine neurotransmission underlies psychotic episodes as observed in patients with some ...
Background: Schizophrenia is a disease diagnosed by visible signs and symptoms from late adolescence...
Among the many neuromodulators used by the mammalian brain to regulate circuit function and plastici...
Dysfunction in both the dopaminergic and glutamatergic systems has been implicated in the pathophysi...
The cloning of the dopamine (DA) D2 receptor now permits the characterization and regulation of D2 m...
Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. ...
Presynaptic increase in striatal dopamine is the primary dopaminergic abnormality in schizophrenia, ...
Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia. The revised d...
Published online 7 August 2007.There is growing evidence implicating dysfunctional glutamatergic neu...
Based on the observation that antipsychotic medications dis-play antagonist properties at dopamine D...
Negative symptoms (NS) represent a heterogeneous dimension of schizophrenia (SCZ), associated with a...
Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. ...
The dopamine D2 and D3 receptors are implicated in schizophrenia and its pharmacological treatments....